BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
BOSTON SCIENTIFIC CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$45.05+0.66 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $66.44B
- P/E (TTM)
- 18.2
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
69.0%+4.0 pts over 5 years
Operating margin
18.0%+18.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +19.9% | +16.5% | +15.2% | +10.4% | |
| Gross profit | +20.6% | +16.7% | +16.5% | +10.1% | |
| Operating income | +38.8% | +29.9% | – | – | |
| EPS, diluted | +55.2% | +62.8% | – | – | |
| Free cash flow | +38.3% | +57.4% | +26.4% | +23.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | 0.90 | 1.82 | 1.62 | |
| Debt to equity | – | – | 0.47 | |
| Net debt to EBITDA | 3.96× | 6.85× | 1.90× | |
| Interest coverage | 1.9× | -0.2× | 10.4× | |
| Inventory turnover | 2.5× | 2.4× | 2.2× | |
| Capex to revenue | 4.5% | 3.8% | 4.4% | |
| Diluted shares | 1.38B | 1.42B | 1.49B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Boston Scientific generated $13.87B from operations and spent $3.66B on capital expenditure, dividends and share buybacks. 96% of that went back into the business.
Generated
$13.87B
Used
$3.66B
Capital expenditure$3.52B96%Dividends$138.00M4%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero$4.53B
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income$4.53B vs –
- Less leverageLong-term debt to assets fell22.8% → 25.5%
- Better liquidityCurrent ratio rose1.08 → 1.62
- No dilutionShare count did not rise1.49B → 1.49B
- Gross margin improvedGross margin up on the prior year68.61% → 69.01%
- More efficientAsset turnover rose0.48 → 0.51